
OrbitalRx
$5.2M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
OrbitalRx is currently valued at $25.2M as of October 20, 2025. The company has raised a total of $7.4M in funding.
Capital Efficiency
With a capital efficiency ratio of 3.42x, OrbitalRx has achieved a valuation that is 3.42 times the total capital raised. This metric indicates strong capital efficiency and effective deployment of investor funds.
Investment Perspective
OrbitalRx's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is OrbitalRx Worth in 2025?
As of 2025, OrbitalRx is valued at $25.2M, based on the company's Seed Round funding round in October 20, 2025. This valuation positions OrbitalRx as one of the leading private companies in the sector.
OrbitalRx Valuation History
OrbitalRx's funding history demonstrates steady growth and investor confidence.
How OrbitalRx Valuation is Determined
Private company valuations like OrbitalRx's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
OrbitalRx Valuation FAQs
Is OrbitalRx profitable?
OrbitalRx has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does OrbitalRx's valuation compare to competitors?
OrbitalRx is valued at $25.2M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will OrbitalRx IPO?
OrbitalRx has not announced plans for an initial public offering. Until an IPO, investors can access OrbitalRx shares through secondary market platforms.